Latest News for Harmony Biosciences Stock (NASDAQ:HRMY)

Friday, November 17, 2023

Watching Harmony Biosciences; Hearing Zacks Home Run Investor Newsletter Picks Stock
Benzinga Newsdesk - Nov 17, 2023, 11:01AM

Wednesday, November 01, 2023

Needham Reiterates Buy on Harmony Biosciences, Maintains $53 Price Target
Benzinga Newsdesk - Nov 1, 2023, 6:28AM
Raymond James Maintains Outperform on Harmony Biosciences, Raises Price Target to $27
Benzinga Newsdesk - Nov 1, 2023, 6:06AM

Tuesday, October 31, 2023

Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Oct 31, 2023, 1:36PM
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday
Lisa Levin - Oct 31, 2023, 12:04PM
Harmony Biosciences Q3 2023 EPS $0.97 May Not Compare To $0.65 Estimate, Revenue $160.268M May Not Compare To $148.608M Estimate
Benzinga Newsdesk - Oct 31, 2023, 8:16AM
Earnings Scheduled For October 31, 2023
Benzinga Insights - Oct 31, 2023, 5:44AM

Monday, October 30, 2023

Harmony Biosciences's Earnings Outlook
Benzinga Insights - Oct 30, 2023, 3:01PM

Monday, October 16, 2023

Why Harmony Biosciences Stock Is Trading Higher Today
Ryan Gustafson - Oct 16, 2023, 3:41PM
Harmony Biosciences shares are trading higher as the stock rebounds after falling Friday on Phase 3 INTUNE study data.
Benzinga Newsdesk - Oct 16, 2023, 2:05PM
Piper Sandler Maintains Overweight on Harmony Biosciences, Lowers Price Target to $42
Benzinga Newsdesk - Oct 16, 2023, 1:27PM
Analyst Ratings for Harmony Biosciences
Benzinga Insights - Oct 16, 2023, 8:00AM
Needham Maintains Buy on Harmony Biosciences, Lowers Price Target to $53
Benzinga Newsdesk - Oct 16, 2023, 6:04AM
Raymond James Maintains Outperform on Harmony Biosciences, Lowers Price Target to $26
Benzinga Newsdesk - Oct 16, 2023, 4:21AM

Friday, October 13, 2023

Nasdaq Down Over 1%; Wells Fargo Beats Expectations
Lisa Levin - Oct 13, 2023, 2:50PM
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights - Oct 13, 2023, 1:31PM
Why Belden Shares Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin - Oct 13, 2023, 1:14PM
Crude Oil Rises Sharply; Citigroup Posts Upbeat Earnings
Lisa Levin - Oct 13, 2023, 12:01PM
Why Is Sleep Disorder Related Harmony Biosciences Stock Trading Lower Today?
Vandana Singh - Oct 13, 2023, 10:22AM
Harmony Biosciences shares are trading lower after the company reported topline data from its Phase 3 INTUNE study of pitolisant for IH, noting no statistically significant difference was observed between pitolisant and placebo on ESS.
Benzinga Newsdesk - Oct 13, 2023, 8:10AM
Harmony Biosciences' Releases Topline Results From INTUNE Phase 3 Study Of Pitolisant For Idiopathic Hypersomnia; No Statistically Significant Difference Was Observed Between Pitolisant And Placebo Groups On Epworth Sleepiness Scale, The Primary Endpoint
Benzinga Newsdesk - Oct 13, 2023, 8:05AM

Wednesday, October 11, 2023

New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies
Jelena Martinovic - Oct 11, 2023, 9:25AM

Thursday, October 05, 2023

Harmony Biosciences Presents New Secondary Outcome Data From Phase 2 Signal Detection Study In Patients With Prader-Willi Syndrome
Benzinga Newsdesk - Oct 5, 2023, 8:07AM

Wednesday, October 04, 2023

Mizuho Reiterates Buy on Harmony Biosciences, Maintains $54 Price Target
Benzinga Newsdesk - Oct 4, 2023, 10:39AM
Harmony Biosciences On Sept 28, Received Notice From Novugen Pharma & Lupin Seeking Approval To Manufacture, Sell A Generic Version Of Wakix In U.S.
Benzinga Newsdesk - Oct 4, 2023, 8:12AM

Wednesday, September 27, 2023

Harmony Biosciences Announces Extension Of Tender Offer To Acquire Zynerba Pharmaceuticals, Inc.
Benzinga Newsdesk - Sep 27, 2023, 8:04AM

Tuesday, September 26, 2023

Goldman Sachs Maintains Sell on Harmony Biosciences, Lowers Price Target to $31
Benzinga Newsdesk - Sep 26, 2023, 8:30AM

Monday, September 25, 2023

Expert Ratings for Harmony Biosciences
Benzinga Insights - Sep 25, 2023, 5:00PM
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
Benzinga Insights - Sep 25, 2023, 11:00AM
Harmony Biosciences shares are trading lower after Goldman Sachs downgraded the stock from Neutral to Sell and lowered its price target from $40 to $31.
Benzinga Newsdesk - Sep 25, 2023, 10:04AM
Goldman Sachs Downgrades Harmony Biosciences to Sell, Lowers Price Target to $31
Benzinga Newsdesk - Sep 25, 2023, 8:09AM

Friday, September 22, 2023

Needham Reiterates Buy on Harmony Biosciences, Maintains $66 Price Target
Benzinga Newsdesk - Sep 22, 2023, 11:09AM

Thursday, September 21, 2023

Tuesday, September 19, 2023

Mizuho Maintains Buy on Harmony Biosciences, Maintains $54 Price Target
Benzinga Newsdesk - Sep 19, 2023, 10:22AM

Thursday, September 07, 2023

9 Analysts Have This to Say About Harmony Biosciences
Benzinga Insights - Sep 7, 2023, 5:00PM
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023
Benzinga Insights - Sep 7, 2023, 11:00AM
Harmony Biosciences shares are trading higher after the company was granted Orphan Drug designation for Pitolisant.
Benzinga Newsdesk - Sep 7, 2023, 9:13AM
Harmony Biosciences Announces U.S. FDA Orphan Drug Designation For Pitolisant For Treatment Of Idiopathic Hypersomnia
Benzinga Newsdesk - Sep 7, 2023, 8:07AM
Berenberg Initiates Coverage On Harmony Biosciences with Buy Rating, Announces Price Target of $59
Benzinga Newsdesk - Sep 7, 2023, 5:53AM

Tuesday, August 29, 2023

Mizuho Reiterates Buy on Harmony Biosciences, Maintains $54 Price Target
Benzinga Newsdesk - Aug 29, 2023, 9:39AM

Monday, August 28, 2023

Harmony Biosciences Commented On The Favorable Decision By The U.S. Patent And Trademark Office To Deny A Petition For Reexamination Concerning A Patent Covering The Active Ingredient In Wakix (Pitolisant)
Benzinga Newsdesk - Aug 28, 2023, 8:06AM

Tuesday, August 22, 2023

Expert Ratings for Harmony Biosciences
Benzinga Insights - Aug 22, 2023, 2:00PM
Cantor Fitzgerald Reiterates Overweight on Harmony Biosciences, Maintains $75 Price Target
Benzinga Newsdesk - Aug 22, 2023, 9:45AM

Tuesday, August 15, 2023

Needham Reiterates Buy on Harmony Biosciences, Maintains $66 Price Target
Benzinga Newsdesk - Aug 15, 2023, 6:07AM

Monday, August 14, 2023

Crude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike Higher
Lisa Levin - Aug 14, 2023, 2:52PM
Health Care Company Harmony Biosciences Announces Acquisition of Zynerba Pharmaceuticals
Benzinga Insights - Aug 14, 2023, 11:10AM
A Look Into Healthcare Sector Value Stocks
Benzinga Insights - Aug 14, 2023, 10:44AM
Why Zynerba Pharmaceuticals Stock Is Skyrocketing Today?
Erica Kollmann - Aug 14, 2023, 10:21AM
Zynerba Pharmaceuticals Cs Shares To Resume Trade At 8:00 A.M. ET
Charles Gross - Aug 14, 2023, 7:39AM

Open-	Close-
Vol / Avg.0 / 799.309K	Mkt Cap1.672B
Day Range- - -	52 Wk Range18.611 - 61.940

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Harmony Biosciences Stock (NASDAQ:HRMY)

Friday, November 17, 2023

Wednesday, November 01, 2023

Tuesday, October 31, 2023

Monday, October 30, 2023

Monday, October 16, 2023

Friday, October 13, 2023

Wednesday, October 11, 2023

Thursday, October 05, 2023

Wednesday, October 04, 2023

Wednesday, September 27, 2023

Tuesday, September 26, 2023

Monday, September 25, 2023

Friday, September 22, 2023

Thursday, September 21, 2023

Tuesday, September 19, 2023

Thursday, September 07, 2023

Tuesday, August 29, 2023

Monday, August 28, 2023

Tuesday, August 22, 2023

Tuesday, August 15, 2023

Monday, August 14, 2023